Integra LifeSciences to Host Analyst Forum on November 15, 2004
PLAINSBORO, N.J., Nov. 2, 2004 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will host an Analyst Forum on Monday, November 15, 2004 at 3:00 PM Eastern Time at the Hilton Times Square Hotel in New York City. The meeting, which will be hosted by Stuart Essig, Integra's President and Chief Executive Officer, will feature an overview of our business, a review of our operations and financial performance, and a detailed discussion of our products and pipeline. Our senior clinical, sales and marketing teams will also discuss clinical results and marketing strategies for our key products. Joseph A. Molnar, M.D., Ph.D., F.A.C.S., Associate Director of Burn Unit, Assistant Professor, Department of Plastic and Reconstructive Surgery, Wake Forest University School of Medicine, will also make a presentation on his clinical experience with several of our products. A question and answer session will follow the formal presentations.
The Analyst Forum is open to all analysts and investors. Those who wish to attend the Analyst Forum in person should send an email to the attention of Dorothy Smith (dsmith@Integra-LS.com) by November 10, 2004 requesting a reservation to attend in person. Access to the live presentations will be available by dialing (973) 935-8511 or through a listen-only webcast via a link provided on the home page of Integra's website at www.Integra-LS.com. Listeners participating via telephone or webcast will not be able to ask questions during the question and answer session.
A replay of the Analyst Forum will be accessible starting one hour following the live event. Access to the replay will be available through November 29, 2004 by dialing (973) 341-3080 (access code 5249673) or through the webcast accessible on our home page.
Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, plastic and reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. We have approximately 1,200 employees. Please visit our website at (http://www.Integra-LS.com).
Statements made in the upcoming Analyst Forum may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results. Forward-looking factors that may be discussed include, but are not limited to, expected financial results, new product development, governmental approvals, market potential, and expected sales and potential therapeutic applications of new products. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2003 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
John B. Henneman, III (Executive Vice President and Chief Administrative Officer)
(609) 936-2481
jhenneman@Integra-LS.com
or
Maria Platsis (Corporate Development & IR)
609-936-2333
mplatsis@Integra-LS.com
SOURCE: Integra LifeSciences Holdings Corporation